Vaxcyte Jumps 54% on Vaccine Results, PTC Gains 34% on $22.6B Deal, RXO Rises 24% on Takeover, InTest Rally on Orders

Mumbai, Oct 6: US-listed stocks saw notable company-specific developments on October 5, 2026, across healthcare, technology, defence, industrials and space. Clinical updates, acquisitions, new orders, financing deals and government contracts drove significant movements in individual stocks. The session highlighted how fresh corporate developments continued to influence investor sentiment across diverse sectors. 

Vaxcyte Shares Surge 54% After October 5 Phase 3 Vaccine Results Impress Investors 

Vaxcyte shares jumped sharply on October 5 after the company reported positive topline results from the OPUS-1 pivotal Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. The stock closed at $56.48 on October 2 before opening at $87.21 on October 5, marking an opening gain of about 54.4%. The shares then climbed to an intraday high of $90.75 and touched a low of $73.87 during the session. 

At around 11:55 a.m. ET, Vaxcyte (NASDAQ: PCVX) was trading at approximately $75.28, up 33.30% from the previous close. This showed that the stock remained significantly higher following the clinical update, although it had given up part of its initial gains after reaching the session high. 

The rally followed results showing that VAX-31 met all prespecified primary endpoints across the age groups studied against Prevnar 20 and Capvaxive. In adults aged 50 and older, VAX-31 met the non-inferiority threshold for all 28 serotypes shared with the comparator vaccines. The three serotypes unique to VAX-31 and cross-reactive serotype 20B also met superiority criteria. 

The Phase 3 trial enrolled 4,047 participants across approximately 30 sites in the United States. Vaxcyte said VAX-31 was well tolerated, with a safety profile similar to PCV20 and PCV21. No serious adverse events were considered related to the study vaccines, while no participants discontinued the study because of adverse events. 

The company expects to report results from its OPUS-2 and OPUS-3 adult Phase 3 trials in the first half of 2027, with a planned Biologics License Application submission in the first half of 2028. The latest results therefore provide a clinical milestone for VAX-31 while investors continue to assess the programme’s remaining trial and regulatory milestones. 

PTC Shares Surge 34% After Schneider Electric Announces $22.6 Billion Takeover 

Schneider Electric has agreed to acquire Boston-based industrial software maker PTC for $205 per share in cash, valuing PTC’s equity at approximately $22.6 billion. The transaction represents a 42.3% premium to PTC’s previous closing price and a 46.1% premium to its 30-day volume-weighted average share price. 

The announcement triggered a sharp reaction in PTC shares. The stock opened at $195.84 on October 5, compared with its previous close of approximately $144.06, implying an opening gain of nearly 36%. During the session, PTC reached an intraday high of $196.05 and a low of $192.78. At around 12:04 p.m. ET, the shares were trading at $192.84, up 33.88%, showing that the stock remained close to the proposed acquisition price as investors responded to the cash offer. 

Schneider Electric said the transaction gives PTC an enterprise value of approximately $23.7 billion, including net debt. PTC, which employs more than 7,000 people and serves over 30,000 customers, develops computer-aided design and product lifecycle management software. The company generated approximately $2.7 billion in revenue in 2025, with an adjusted EBITA margin of around 40%. 

The acquisition is expected to generate $281 million in annual cost synergies by the third year, alongside approximately $900 million in revenue synergies from cross-selling products across the companies’ customer bases. Schneider Electric expects the deal to increase adjusted earnings per share by a low single-digit percentage in the first full year of consolidation, rising to mid-to-high single-digit growth when full run-rate synergies are included. 

The approximately $24.8 billion cash consideration will be funded through a combination of new shares and debt. Schneider Electric plans to raise around $5.6 billion-$6.8 billion through an accelerated bookbuild and take on approximately $18 billion-$19.1 billion in debt. Completion is expected in the third quarter of 2027, subject to shareholder and regulatory approvals. 

Also Read: What Is the New York Stock Exchange (NYSE)?  

RXO Shares Jump 24% After $5.8 Billion C.H. Robinson Acquisition Deal 

C.H. Robinson Worldwide has agreed to acquire RXO in a $5.8 billion stock-and-cash transaction, expanding its presence in North American truck brokerage and adding greater scale across logistics and delivery services. RXO shareholders will receive $17.25 in cash and 0.0856 C.H. Robinson shares for each RXO share, valuing the transaction at $30.25 per share, a 29% premium to RXO’s previous closing price. 

The deal triggered a sharp divergence in the two companies’ shares. RXO closed at $23.38 on October 2 and opened at $29.00 on October 5, representing an opening gain of about 24%. The stock subsequently reached an intraday high of $29.11 and a low of $28.03. At around 12:07 p.m. ET, RXO was trading at $28.34, up 21.23%, as investors continued to price the shares closer to the proposed transaction value. 

C.H. Robinson shares, meanwhile, fell sharply following the announcement, reflecting the market’s response to the acquisition and its funding and integration implications. The combined company is expected to have an enterprise value exceeding $25 billion, bringing together operations spanning truck brokerage, managed transportation, expedited delivery and last-mile services. 

C.H. Robinson expects approximately $300 million in annual cost savings within two years, partly through deploying its Lean AI operating model across RXO. RXO’s technology-enabled truck brokerage operations will primarily be integrated into C.H. Robinson’s North American Surface Transportation business, which accounts for more than two-thirds of its revenue. 

The acquisition is also expected to expand C.H. Robinson’s US last-mile delivery coverage and strengthen its ability to pursue larger corporate customers. Completion remains subject to customary closing conditions and regulatory approvals. 

InTest Shares Jump 24% After Record Q3 Orders Signal Stronger Semiconductor Demand 

InTest Corporation shares jumped on October 5 after the company said it expects record third-quarter orders of $48 million-$50 million, representing growth of 28%-33% from the same period last year. The surge in orders, led by back-end semiconductor demand, is expected to push the company’s book-to-bill ratio above 1.3x and strengthen its revenue outlook. 

InTest (NYSE American: INTT) opened at $13.12, compared with the previous close of approximately $12.27, an opening gain of nearly 7%. The shares then climbed to an intraday high of $15.44, while the session low remained at $13.12. At around 12:45 p.m. ET, INTT was trading at $15.26, up 24.39%, keeping the stock close to its session high as investors reacted to the stronger order outlook. 

The company expects third-quarter revenue to come in at the high end of its $33 million-$35 million guidance range, representing growth of more than 30% from $26.2 million in the third quarter of 2025. InTest also expects backlog to reach $58 million-$60 million at September 30, up approximately 28%-32% from $45.4 million at the end of June. 

Management attributed the stronger order activity primarily to rising semiconductor demand, with customer capacity expansions being supported partly by AI-driven data-centre demand. Newer products, including high-powered chillers and advanced manipulators, are also contributing to demand as customers address increasing power-conversion and mixed-signal and analogue testing requirements. 

The company expects both Q3 and full-year 2026 revenue to be at the high end of its respective guidance ranges. InTest is scheduled to report its final third-quarter results on November 6, 2026. 

NeuroOne Shares Rise 3.6% As Q4 Revenue Jumps 38.4% To $3.8 Million 

NeuroOne Medical Technologies reported preliminary unaudited product revenue of approximately $3.8 million for the fourth fiscal quarter ended September 30, 2026, up 38.4% from about $2.7 million a year earlier. The company also expects full-year fiscal 2026 revenue of approximately $10.5 million, representing 15.6% year-on-year growth and reaching the top of its previously announced guidance range. 

The revenue update was followed by a positive move in NeuroOne shares during Monday’s session. NeuroOne (NASDAQ: NMTC) opened at $1.18 on October 5, compared with the previous close of approximately $1.12, an opening gain of about 5.4%. The stock climbed as high as $1.35 and fell to an intraday low of $1.12. At around 12:34 p.m. ET, NMTC was trading at $1.16, up 3.57%. 

The company’s order pipeline also strengthened during the quarter. NeuroOne secured a $4.5 million product purchase order in September, of which approximately $1 million was shipped during the month. Shipments of the remaining $3.6 million are expected to begin in the first quarter of fiscal 2027 and continue into the second quarter, subject to manufacturing and delivery schedules. 

Total open purchase orders for shipments through the first quarter of fiscal 2027 reached $5.4 million as of September 30, while product orders increased 24.2% in fiscal 2026 compared with the previous year. 

NeuroOne markets electrode technology and ablation systems for neurological disorders and has four FDA-cleared product families. The company expects to report complete fourth-quarter and fiscal 2026 results in December 2026, following completion of its year-end accounting and audit procedures. 

Also Read: How to invest in US stocks

GE HealthCare Shares Rise 1.3% After $945 Million Sofie Biosciences Acquisition 

GE HealthCare has agreed to acquire privately held Sofie Biosciences for $945 million in cash, strengthening its pharmaceutical diagnostics business and expanding its ability to manufacture and distribute PET imaging drugs. The transaction will also give GE HealthCare US rights to FAPI-74, an experimental PET imaging agent in late-stage testing that could be used to detect several types of cancer. 

The market reaction was positive but relatively modest. GE HealthCare (NASDAQ: GEHC) closed at $64.29 on October 2 and opened at $63.62 on October 5, initially declining about 1%. The shares subsequently recovered, reaching an intraday high of $65.24 and a low of $63.37. At around 12:22 p.m. ET, GEHC was trading at $65.15, up 1.34% from the previous close, indicating that the shares had moved higher as the session progressed following the acquisition announcement. 

The Sofie deal expands GE HealthCare’s exposure to the growing radiopharmaceuticals market, adding products that complement its diagnostic imaging systems. GE HealthCare already has a radiopharma portfolio that includes Flyrcado, a US FDA-approved PET imaging agent used to detect coronary artery disease, myocardial ischaemia and heart attacks. 

Sofie develops products including radioisotopes used in PET scans and operates facilities that manufacture and distribute radiopharmaceuticals to hospitals and imaging centres. GE HealthCare said Sofie would continue manufacturing products for existing customers, including other radiopharmaceutical companies, after the acquisition closes. 

The transaction comes amid increased consolidation in the radiopharmaceuticals industry, with Curium agreeing in August to acquire Lantheus in a deal valued at up to $8 billion. GE HealthCare expects the Sofie acquisition to close in the first half of 2027, subject to customary closing conditions. 

Qualcomm Shares Fall 1.5% Despite Huawei AI Chip Patent Licensing Deal 

Qualcomm shares were initially indicated higher overnight after the chipmaker agreed to license patents covering Huawei Technologies’ LogicFolding chip technology, but the stock moved lower during Monday’s session. The multiyear agreement forms part of a broader cross-licensing arrangement covering technologies related to 5G devices, AI services, near- and co-packaged optics and networking. 

The initial reaction was positive, with Qualcomm shares reportedly gaining about 2% overnight following news of the agreement. However, that momentum faded after the US market opened. Qualcomm (NASDAQ: QCOM) opened at $185.08 on October 5, compared with the previous close of approximately $184.70, before reaching an intraday high of $185.48 and a low of $180.48. At around 12:27 p.m. ET, the stock was trading at $181.86, down 1.54%. 

The financial terms of the patent agreement were not disclosed, while the deal remains subject to review by the US Federal Trade Commission. Huawei expects the overall value of its patent licensing agreements to exceed $6.9 billion following the Qualcomm agreement, according to a company spokesperson cited by Bloomberg. 

Huawei unveiled LogicFolding in May as a chip-design technique that rearranges and vertically folds circuitry to shorten signal paths. The approach is designed to improve chip performance and efficiency without relying solely on more advanced manufacturing processes. The technology is particularly relevant to Huawei as US restrictions have limited its access to advanced semiconductor manufacturing equipment and Nvidia’s leading AI chips. 

For Qualcomm, the agreement adds another development to a series of recent business catalysts. The company has also secured a major multigeneration AI chip deal with Amazon and extended its patent-licensing agreement with Apple. Qualcomm shares remain up about 9.8% year to date, despite Monday’s decline. 

Flex Shares Rise 0.7% After Cloud Unit Secures $2 Billion Investment 

Flex has secured a $2 billion investment in its Cloud and Power Infrastructure segment, Axiom Solutions International, as the company prepares to separate the business into an independent publicly traded company in the first quarter of 2027. The investment, led by General Catalyst and Koch Equity Development, values Axiom at an initial enterprise value of $37.5 billion. 

Flex shares initially moved higher following the announcement and remained in positive territory during Monday’s session. Flex (NASDAQ: FLEX) opened at $116.99 on October 5, compared with the previous close of approximately $116.61, and climbed to an intraday high of $121.48. The shares touched a low of $116.50 during the session. At around 12:30 p.m. ET, FLEX was trading at $117.53, up 0.71%. 

The investment will provide equity funding for Axiom’s pending acquisition of EPC Power, with Flex also securing committed term-loan financing for the remaining portion of the transaction. Net proceeds from the preferred-stock sale may also be used to repay related bridge financing, fund preferred-stock dividends or support general corporate purposes. 

The convertible preferred stock will carry a 10% annual cash dividend before the separation. Following the separation, the dividend will step down to 6% in cash or 7% if paid in kind, with the rate subject to increases after the fifth anniversary of the separation. 

The transaction strengthens Axiom’s capital position ahead of its planned independence, while allowing Flex to fund the expansion of the cloud infrastructure business without retaining the segment as part of its long-term corporate structure. The investment remains subject to regulatory approvals and customary closing conditions. 

Also Read: US Stock Market Timings 

Rezolve AI Shares Rise 7.75% After Mastercard Reseller Agreement 

Rezolve AI shares rose on October 5 after the company announced a worldwide reseller agreement with Mastercard to distribute its AI-powered commerce technology. The stock had closed at $2.06 previously and opened at $2.23, before reaching an intraday high of $2.27 and a low of $2.16. At 1:17 p.m. ET, Rezolve AI traded at $2.22, up about 7.75%. 

Under the non-exclusive agreement, Mastercard is authorised to market, offer and sell subscriptions to Rezolve AI’s software and SaaS services globally. Mastercard will coordinate the sales process and contract directly with resale customers, creating a new channel for Rezolve AI to reach businesses through Mastercard’s customer relationships. 

The agreement covers conversational commerce, intelligent search and product discovery, catalogue enrichment, personalisation, recommendations, and cart and checkout orchestration. Individual deployments will be governed by separate statements of work. 

Rezolve AI said the arrangement establishes a commercial framework for Mastercard-led customer evaluations, presentations, proposals and product demonstrations, with the potential to convert opportunities into deployments and subscription revenue. The company provides technology designed to connect customer intent with products and support shopping journeys from discovery through checkout, including AI-driven recommendations and purchase coordination. 

DFDV Shares Fall After Preliminary Q3 Estimates Show Strong SOL Treasury Growth 

DeFi Development Corp. (Nasdaq: DFDV) shares traded lower on October 5 despite the company reporting strong preliminary Q3 growth metrics and continued expansion of its Solana (SOL) treasury. The stock had closed at $5.54 previously and opened at $5.54, before reaching an intraday high of $5.60 and a low of $5.26. At 12:59 p.m. ET, DFDV traded at $5.28, down about 4.69% from the previous close. 

The company said it added approximately 26,203 SOL to its treasury since September 28, taking total SOL and SOL equivalents to about 2.56 million, valued at approximately $302 million. Holdings have increased by roughly 11% since the August 12 earnings update. 

Preliminary September 30 estimates indicate double-digit growth in SOL per share and more than 100% growth in net asset value per share compared with August 12. DFDV also expects double-digit growth in total SOL and equivalents, lower notional SOL-denominated borrowings and more than 100% growth in cash and cash equivalents. 

The company also highlighted CHAD, its Nasdaq-listed variable-rate preferred stock, which paid its first dividend on October 1. CHAD currently carries a 13% annual dividend rate on its $10 stated amount, with DFDV positioning the instrument as an additional source of capital for further SOL accumulation. 

Cenovus  Announces C$5.7 Billion Athabasca Oil Acquisition Deal; Shares Fall 2.50%  

Cenovus Energy shares declined on October 5 after the company agreed to acquire Athabasca Oil in a cash-and-stock transaction valued at approximately C$5.7 billion (US$4 billion) in enterprise value. Cenovus shares had closed at $32.40 previously and opened at $31.90, before reaching an intraday high of $32.15 and a low of $30.74. At 1:09 p.m. ET, the stock traded at $31.59, down about 2.50%. 

The acquisition will add roughly 45,000 barrels of oil equivalent per day to Cenovus’s production and expand its oil sands resource base. Athabasca’s thermal operations currently produce about 40,000 barrels per day, with Cenovus targeting approximately 115,000 barrels per day by 2032 through asset optimisation, Leismer expansion and accelerated development of the Corner project. 

Cenovus expects to spend approximately C$700 million to C$800 million annually through 2030 on the expanded thermal development plan. The company also expects about C$85 million in annual corporate and commercial synergies, while the transaction is expected to be accretive to adjusted funds flow per share in 2027. 

Up to 75% of the consideration can be paid in cash, with the remainder in Cenovus shares. The transaction has been approved by both boards and is expected to close in December, subject to regulatory and shareholder approvals. Athabasca shares rose 13.98% following the announcement. 

Mobix Labs Announces Business Combination Agreement with Winner Water Services Deal; Shares Fall 23.43%  

Mobix Labs announced a definitive business combination agreement with Winner Water Services, which is set to join Mobix Labs’ National Security Matters platform. The stock had closed at $0.85 previously and opened at $0.84, before reaching an intraday high of $0.87 and a low of $0.64. At 1:27 p.m. ET, Mobix Labs traded at $0.65, down 23.43%. 

Winner Water Services, based in Pennsylvania, recovers rare earth elements, scandium and alumina from coal ash impoundments. The company and its research partners have received six consecutive Department of Energy and Department of Defense awards totalling $53 million over 10 years, supporting its critical-minerals development. 

In August 2026, Winner broke ground on a rare earth extraction demonstration plant at the National Carbon Capture Center in Alabama. Its addition is expected to form part of the National Security Matters initiative being assembled through Special Project Delivery’s previously announced combination with Mobix Labs. 

The Winner transaction is expected to close alongside Special Project Delivery’s combination with Mobix Labs, subject to required approvals and customary closing conditions. The companies said the proposed transactions, federal funding and plant construction remain subject to risks that could affect their timing and completion. 

Also Read: What Are Fractional Shares? 

TRex Bio Sets $133 Million IPO Range As Pipeline Advances Towards Clinical Trials 

TRex Bio has set a price range for its proposed initial public offering, seeking to raise up to $133.3 million as the clinical-stage biotechnology company advances treatments for autoimmune and inflammatory disorders. The South San Francisco-based company plans to offer 8.33 million shares at $14 to $16 each. At the top end, its post-offering valuation would be about $439 million. 

TRex Bio is developing therapies based on tissue regulatory T cell (Treg) biology, aiming to restore immune balance rather than relying on broad systemic immunosuppression. Its lead candidate, TRB-061, is a TNFR2 agonist in Phase 1b testing for moderate-to-severe atopic dermatitis, with topline results expected in mid-2027. 

The company is also developing TRB-071, which targets CD30 and is designed to suppress inflammatory pathways while expanding tissue Tregs. Phase 1 trials are expected to begin in the first half of 2027, following IND-enabling studies. 

TRex Bio is backed by investors including Eli Lilly, Pfizer Ventures and Johnson & Johnson Innovation. Lilly has indicated interest in purchasing additional shares to maintain an ownership stake of up to 19.9%. Lilly is also advancing TRB-051, discovered through TRex Bio’s platform, towards a Phase 2a trial for cutaneous lupus. 

IPO proceeds are expected to fund clinical development and operations. TRex Bio has applied to list on Nasdaq under the ticker TRXB, with J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush PacGrow as joint bookrunners. 

Retension Pharmaceuticals Sets $11–$13 IPO Range To Raise Up To $43 Million 

Retension Pharmaceuticals plans to sell 3.3 million shares at $11 to $13 each in its initial public offering, with the clinical-stage biopharmaceutical company seeking to fund development of medicines for hypertension and other cardiovascular diseases. At the $12 midpoint, the Falls Church, Virginia-based company expects net proceeds of approximately $33.8 million. 

If underwriters exercise their option to purchase an additional 495,000 shares, net proceeds could rise to about $39.4 million. Retension said the IPO proceeds, together with its existing resources, are expected to fund operating expenses and capital-spending requirements for at least the next 21 months. 

Following the IPO and private placement, Retension expects to have approximately 8.38 million shares outstanding, assuming the overallotment option is exercised. At the $12 midpoint, this would imply a market capitalisation of about $100.5 million. 

The company is focused on developing treatments for hypertension and other cardiovascular conditions, with proceeds from the offering intended to support its operations and development programmes. Retension has applied to list its shares on the Nasdaq Capital Market under the ticker RTSN. 

Neighborhood Intelligence Shares Fall 23.91% After $45.5 Million Equity Financing 

Neighborhood Intelligence shares fell sharply on October 5 after the company announced a $45.5 million registered direct equity offering priced at $2.76 per share. The stock had closed at $2.76 previously and opened at $2.60, before reaching an intraday high of $2.60 and a low of $2.06. At 1:39 p.m. ET, shares traded at $2.10, down 23.91%. 

The company agreed to sell 16.49 million shares, or pre-funded warrants, alongside warrants covering up to 16.12 million additional shares. The warrants carry an exercise price of $3.45, a 25% premium to the closing price, cannot be exercised for six months and expire five years after becoming exercisable. 

The financing was led by funds managed by Highbridge Capital Management, with participation from management, including Executive Chairman and CEO Marcus Lemonis. Lemonis will receive shares at the same price but has opted not to receive the accompanying warrants. 

Neighborhood Intelligence said its core business continues to show revenue momentum, while gross margins are expected to exceed 30%. Cost reductions and merger synergies are also progressing ahead of schedule. Proceeds will support merger synergies, inventory, working capital and general corporate purposes. 

The company also plans to reduce its ATM equity facility from $200 million to approximately $75 million. If fully exercised for cash, the warrants could generate an additional $56.25 million in gross proceeds. 

Medical Stocks Fall as SeaStar Raises $3.3 Million and Utah Extends Tender Offer 

SeaStar Medical and Utah Medical Products shares moved lower on October 5 as investors reacted to separate corporate updates involving financing and shareholder actions. SeaStar Medical shares had closed at $4.69 and opened at $3.62, reaching a high of $3.74 and a low of $3.50. At 1:40 p.m. ET, the stock traded at $3.53, down 24.73%. Utah Medical shares opened at $74.22 after a previous close of $74.13, reaching $74.28 and $73.22. At 1:45 p.m. ET, they traded at $73.46, down 0.90%. 

SeaStar Medical entered agreements for the immediate exercise of warrants covering up to 854,002 shares at $3.866 each, raising approximately $3.3 million in gross proceeds. The company will issue new warrants covering up to 1.71 million shares at $3.616 each, with different expiry periods. Proceeds will support working capital, capital expenditure and other corporate purposes. 

Meanwhile, Utah Medical extended its tender offer to purchase up to 650,000 shares at $75 each until 5:00 p.m. New York time on October 27. The original deadline was October 7. The extension gives shareholders more time to consider the offer and the company’s third-quarter results, due October 22. Other tender-offer terms remain unchanged. 

Also Read: What Is the S&P 500? A Simple Guide for Everyday Investors

Tutor Perini Jumps 4.2% On $315M Coast Guard Deal As Syntec Optics Surges 12.7% 

Tutor Perini shares rose 4.2% to $86.73 by 11:30 a.m. ET after its subsidiary Perini Management Services won a roughly $315 million U.S. Coast Guard contract to build a fuel pier at Base Kodiak in Alaska. The stock opened at $84.21 against a previous close of $83.26 and reached an intraday high of $87.52. The contract will be added to Tutor Perini’s third-quarter 2026 backlog, with completion expected in September 2030. 

Syntec Optics shares climbed 12.7% to $9.14 after the company announced recurring production orders for actuators used in NASA’s Artemis III rockets. Shares opened at $8.27 versus a previous close of $8.11 and touched $9.25. The orders strengthen the company’s exposure to recurring space and defence programmes. 

Powerus, meanwhile, received an $82 million order for counter-unmanned aerial systems under an existing U.S. government IDIQ contract, marking the second order under the agreement. Despite the contract win, its shares traded between $2.98 and $3.34 after opening at $3.25, compared with a previous close of $3.20. 

Voyager Technologies also secured a $22.4 million U.S. government contract to prototype next-generation satellite deployment systems, while S&K Aerospace received a $4.3 billion U.S. Air Force PROS 7 contract. 

US markets saw a broad mix of company-specific developments, with healthcare, technology, industrial, defence and space companies responding to fresh business updates. Earnings-related milestones, acquisitions, new orders, financing activity and government contracts remained key themes, resulting in notable share-price movements across both large and smaller listed companies. 

Source 

• https://www.nasdaq.com/ 

• spglobal.com/spdji/en/indices/equity/sp-500/ 

• https://www.dowjones.com/ 

• https://www.spglobal.com/spdji/en/indices/equity/dow-jones-industrial-average/ 

• https://www.spglobal.com/spdji/en/indices/equity/sp-500/ 

• https://www.nasdaq.com/market-activity/index/comp 

• https://www.nasdaq.com/market-activity/quotes/nasdaq-ndx-index 

• https://www.spglobal.com/spdji/en/indices/equity/sp-100/ 

• https://www.lseg.com/en/ftse-russell/indices/russell-us 

• https://www.nyse.com/index 

• https://www.nyse.com/index 

• https://www.spglobal.com/spdji/en/indices/equity/dow-jones-transportation-average/ 

• https://www.spglobal.com/spdji/en/indices/equity/dow-jones-utility-average/ 

• https://www.spglobal.com/spdji/en/indices/equity/dow-jones-composite-average/ 

• https://www.nasdaq.com/market-activity/index/sox 

• https://www.cboe.com/tradable_products/vix/